癌癥的治療一直被視為醫(yī)學(xué)上最大的挑戰(zhàn)，近年來，隨著多種嵌合抗原受體-T細(xì)胞（CAR-T）治療產(chǎn)品的獲批上市，為攻克癌癥帶來了新的希望。然而，在臨床應(yīng)用中，CAR-T細(xì)胞治療產(chǎn)品均存在一定的不良反應(yīng)，這提示CAR-T細(xì)胞治療產(chǎn)品的臨床前評價模型十分重要。目前，CAR-T細(xì)胞治療產(chǎn)品的臨床前評價模型主要包括體內(nèi)評價模型和體外評價模型，其中體內(nèi)評價模型包括同源移植小鼠模型、基因工程小鼠模型、人源化小鼠模型、人源腫瘤異體移植模型及非人靈長類動物模型；體外評價模型包括腫瘤類器官模型、器官芯片模型與人工智能預(yù)測模型。對各種評價模型的進(jìn)展及優(yōu)缺點(diǎn)進(jìn)行綜述，以期為CAR-T細(xì)胞治療產(chǎn)品的臨床前評價提供參考。

The treatment of cancer has always been regarded as the biggest challenge in medicine. In recent years, with the approval and launch of various chimeric antigen receptor T cell therapy (CAR-T) products, new hope has been brought to the research of overcoming cancer. However, in clinical practice, CAR-T cell therapy products have certain adverse reactions, which suggests that preclinical evaluation models of CAR-T cell therapy products is crucial. At present, the preclinical evaluation methods for CAR-T cell therapy products mainly include in vivo evaluation models and in vitro evaluation models. In vivo evaluation models include syngeneic mouse model, genetically engineered mouse models, humanized mouse models, patient-derived tumor xenograft models and non-human primate models. In vitro evaluation models include patients derived organoids models, human-on-a-chip models and artificial intelligence prediction. This article aims to review the progress and advantages and disadvantages of various evaluation methods to lay a theoretical and research foundation for preclinical evaluation of CAR-T cell therapy products.

R965.1